ObjectiveTo explore the clinical effect of intravenous immunoglobulin（IVIG）on chronic obstructive pulmonary disease(COPD) and fungal infection. MethodsSeventytwo COPD patients with fungal infection were randomly and equally divided into conventional and intervention group. Patients in conventional group were treated with common schedule for COPD plus antifungal agents; patients in intervention group received 10 g/d IVIG besides routine therapy. Length of hospital stay and prognosis were recorded, and therapeutic effectiveness were evaluated. ResultsThe effectiveness rate of intervention group was significantly higher than that of conventional group (［88.89%,32/36］ vs ［66.67%,24/36］);the average length of hospital stay was significantly shorter than conventional group (［12.62±7.51］ d vs ［20.81±6.92］ d), and mortality was lower than conventional group (［5.56%,2/36］ vs ［22.22%,8/36］), the differences were statistically significant (P<0.05). ConclusionIVIG for treating COPD with invasive pulmonary fungal infection can improve therapeutic efficacy, shorten length of hospital stay and decrease mortality rate.